WHO Committee: MenAfriVac safety

   WHO’s Global Advisory Committee on Vaccine Safety, following review of new data for the meningococcal A conjugate vaccine (MenAfriVac), “concluded that the experience from the first three countries to introduce this vaccine did not indicate any reasons for concern about the vaccine’s safety.” The data reviewed by the Advisory Committee ― at its meeting of 15-16 June 2011 ― were collected in Burkina Faso, Mali and Niger during the September and December 2010 vaccination campaigns and from the surveillance systems, WHO said. The Committee “recognized that it would not be practical to conduct active surveillance on a widespread basis during future immunization activities, (but) it highlighted the need for continuous surveillance as the vaccine is rolled out to ensure that further data on the safety profile of the vaccine can be obtained.” Other issues discussed by the Committee included a new approach for classifying serious adverse events following immunization, information sheets describing the safety profile of important vaccines and the development of a global strategy to enhance vaccine safety capacity in low- and middle-income countries.

Full report: Meeting of the Global Advisory Committee on Vaccine Safety, July 2011
pdf, 339kb